Skip to content

PCMA supports legislation for lowest prices for prescription drugs

Pharmaceutical Care Management Association (PCMA) president and chief executive officer Mark Merritt released the following statement on S. 2554, the Patient Right to Know Drug Prices Act, scheduled to be marked up tomorrow in the U.S.

Table of Contents

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer Mark Merritt released the following statement on S. 2554, the Patient Right to Know Drug Prices Act, scheduled to be marked up tomorrow in the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP):

Mark Merrit

“PCMA strongly supports S. 2554, legislation that will ensure America’s patients always pay the lowest cost for their medications at the pharmacy counter, whether it’s the cash price or the copay.

Fortunately, this legislation aligns with standard practice used by pharmacy benefit managers in the marketplace.

We appreciate the HELP Committee’s prompt action to consider advancing S. 2554, and applaud Senators Susan Collins (R, Maine), Claire McCaskill (D, Mo.), Bill Cassidy (R, La.), Debbie Stabenow (D, Mich.), and John Barrasso (R, Wyo.), for their leadership on this issue.”

Comments

Latest